Sestrin-GATOR2 Modulators for Selective mTORC1 Regulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
mTORC1 dysregulation is associated with a broad spectrum of diseases, including diabetes, epilepsy, neurodegeneration, immune response, and cancer, and existing therapies lack effective methods to selectively modulate its activity.
Innovation Solution
Development of compounds that modulate the Sestrin-GATOR2 interaction to indirectly regulate mTORC1 activity, providing pharmaceutically acceptable compositions for treating associated diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing therapies are used to treat mTORC1 dysregulation, then treatment coverage is provided, but selective modulation of mTORC1 activity is not achieved
Solution Approach 1:
The patent uses Sestrin2 as an intermediary molecule to indirectly modulate mTORC1 activity. Instead of directly targeting mTORC1, the compounds bind to Sestrin2, which then regulates mTORC1 through the natural Sestrin2-GATOR2-mTORC1 pathway. This intermediary approach enables selective modulation while maintaining compatibility with multiple disease states requiring different mTORC1 activity levels.
Solution Approach 2:
The patent changes the molecular target parameter from direct mTORC1 inhibition to Sestrin2-GATOR2 interaction modulation. By targeting the upstream regulatory complex (Sestrin2-GATOR2) rather than mTORC1 itself, the therapy achieves more nuanced and selective control over mTORC1 activity, allowing for disease-specific modulation patterns.
2Reliability
If direct mTORC1 inhibitors are used, then mTORC1 activity is suppressed, but lack of selective modulation prevents effective treatment of diverse diseases
Solution Approach 1:
The patent introduces dynamic regulation by targeting the Sestrin2-GATOR2-mTORC1 signaling axis, which naturally responds to amino acid levels and cellular metabolic states. This dynamic system allows mTORC1 activity to be modulated in response to disease-specific conditions rather than uniformly suppressed, enabling effective treatment across diverse diseases with different metabolic requirements.
Solution Approach 2:
By using Sestrin2 as a mediator between the therapeutic compounds and mTORC1, the system achieves differentiated modulation of mTORC1 activity based on the disease context. The intermediary allows for fine-tuned control that adapts to the specific needs of different disease states, unlike direct inhibitors that provide uniform suppression.
Data Source
AI summary
The present invention provides compounds, compositions thereof, and methods of using the same.